Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2026 (year ended September 2026) was $337.4 billion, up 5.00% from fiscal 2025.
- Revenue
- +5.52%
- EPS
- +258.4%
- Free cash flow
- −7.81%
- Total debt
- +47.1%
Quarter to September 2026, against a year earlier
Follow COR
Alert me
Cencora, Inc. (COR) P/B ratio
As of 5 November 2026, Cencora, Inc. (COR) trades at a P/B ratio of 20.0×. Over the past ten years it has ranged from 0.0× (June 2021) to 509× (December 2022); the current reading is higher than 58% of that period. That is above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2026 | 17.7× | (48.98%) |
| FY2025 | 34.7× | (38.95%) |
| FY2024 | 56.8× | 4.34% |
| FY2023 | 54.4× | (86.25%) |
| FY2022 | 396× | 840.49% |
| FY2021 | 42.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 5.8× | (12.79%) |
| FY2018 | 6.6× | (24.77%) |
| FY2017 | 8.8× | 9.46% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 17.7× | 4.83% |
| Jun 2026 | 16.9× | (1.02%) |
| Mar 2026 | 17.0× | (45.53%) |
| Dec 2025 | 31.3× | (9.73%) |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| CAH Cardinal Health, Inc. compare | n/m |
| MCK McKesson Corporation compare | n/m |
| FOCL FocalTherics compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | 0.1× |
| COSM Cosmos Health Inc. compare | 0.8× |
| HSIC Henry Schein, Inc. compare | 2.5× |
| COR Cencora, Inc. | 20.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on COR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement